A graduate of 麻豆蜜桃AV becomes the first alum to be inducted into the Florida Inventors Hall of Fame.
Phillip Furman (鈥�72) is co-inventor of Retrovir (AZT), the first effective anti-viral drug to slow the symptoms of HIV/AIDS.
The FDA approved AZT in 1987 at the height of the AIDS epidemic, in which claimed
hundreds of thousands of lives. Historians credit AZT for sparking a new era of drug
development for long-term treatment of HIV/AIDS patients.
"Back then a lot of people were dying of AIDS. A vaccine was years away. We believed if we could find the right compound that, given the company鈥檚 expertise, we could develop it quickly and get rapid approval from the FDA," said Furman. "My passion for such research all started while studying to become a virologist at 麻豆蜜桃AV."
Furman earned a master鈥檚 degree from 麻豆蜜桃AV in microbiology, his PhD at Tulane University and went on to build a distinguished career in the pharmaceutical and biotech industries, in which he played a leading role in developing additional drugs to treat diseases such as herpes and Hepatitis C.
鈥淎s the first 麻豆蜜桃AV graduate to be inducted into the Florida Inventors Hall of Fame, Dr. Furman鈥檚 career stands as a testament to the difference that cutting-edge research can make to millions of lives around the world,鈥� said Paul Sanberg, PhD, senior vice president for Research, Innovation and Knowledge Enterprise and chair of the Florida Inventors Hall of Fame Advisory Board. 鈥淗is accomplishments have made medical history, and they continue to inspire new generations of 麻豆蜜桃AV students and faculty scientists and innovators who apply their skills and talents to solving the greatest global problems.鈥�
Furman is one of seven highly accomplished researchers to be inducted into the 2018 class of the Florida Inventors Hall of Fame.
Read more about Furman鈥檚 inductees .